Skip to content

Rewind Therapeutics Raises Further Funding and Provides Sunstone Life Science Ventures A/S as New Investor


Claus Andersson, PhD, joins Rewind’s Board of Administrators

Leuven, Belgium, January 25, 2023 — Rewind Therapeutics, an organization creating first-in-class therapies for demyelination-associated illnesses, in the present day introduced that it has raised further funding, with Sunstone Life Science Ventures A/S becoming a member of as a brand new investor and with participation of present traders Boehringer Ingelheim Enterprise Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.

Claus Andersson, PhD, Basic Companion at Sunstone Life Science Ventures A/S, will be part of Rewind Therapeutics’ Board of Administrators. Monetary particulars of the transaction weren’t disclosed.

The proceeds can be used to advance Rewind Therapeutics’ lead program into scientific improvement and additional broaden the Firm’s pipeline of drug candidates designed to revive the remyelination operate of the central nervous system (CNS). Myelin kinds a protecting layer round neurons and is important for his or her correct functioning. Neurodegenerative issues similar to a number of sclerosis are related to a broken, deteriorating myelin sheath, which finally results in a spread of signs similar to despair, anxiousness, irritability, and even dying as a consequence of a breakdown of the very important neurological features.

“We’re delighted to welcome Sunstone Life Science Ventures as a brand new investor alongside the continued help by our present investor syndicate,” mentioned Anja Harmeier, Chief Govt Officer at Rewind Therapeutics. “The extra financing not solely strengthens our top-tier investor base, but additionally permits us to speed up the development of our lead program into scientific improvement. Moreover, we look ahead to working with Claus Andersson as a brand new member of our Board of Administrators. “

“Halting and even reversing demyelination is a difficult job. The information generated by Rewind Therapeutics up to now helps a really novel mechanism of motion and can enable the Firm to provoke scientific trials in key CNS indications,” mentioned Claus Andersson, PhD, Basic Companion at Sunstone Life Science Ventures A/S. “Furthermore, Rewind has a robust patent property and a staff with lengthy analysis and improvement experience within the discipline of remyelination therapeutics. The mixture of this in depth trade experience and the excessive unmet medical want in neurogenerative issues has satisfied us to affix forces with Rewind´ s present, internationally famend investor syndicate.”

Demyelinating illnesses similar to a number of sclerosis have an effect on tens of millions of sufferers worldwide. Rewind’s strategy relies on making certain correct functioning of myelinating oligodendrocytes and oligodendrocyte precursor cells (OPCs), each of that are drivers of the myelination course of. The Firm’s objective is to determine a novel therapeutic precept that’s universally relevant to all demyelination illnesses. This offers vital therapeutic potential for treating a broad vary of demyelination-inducing situations.


About Rewind Therapeutics
Rewind Therapeutics develops first-in-class therapeutics designed to re-initiate the method of remyelination in sufferers affected by main debilitating illnesses similar to a number of sclerosis, optic neuritis or nerve accidents. A typical characteristic of those diseases is the lack of the myelin sheath, a protecting cowl wrapped across the nerves. Repairing or re-installing this sheath (ie, remyelination) is an important issue for halting or reversing illness development and even curing these illnesses. Rewind’s staff has in depth R&D experience and has constructed a robust patent property for creating novel remyelination therapeutics. Primarily based in Leuven, Belgium, Rewind is backed by top-tier life science traders similar to Boehringer Ingelheim Enterprise Fund, M. Ventures, PMV, Sunstone Life Science Ventures, Gemma Frisius Fonds, and CD3/KU Leuven.

About Sunstone Life Science Ventures
Sunstone Life Science Ventures is an impartial European enterprise capital funding agency based in 2007 by a global staff of trade consultants with mixed entrepreneurial, operational and monetary expertise. Managing complete funds of €500 million, Sunstone Life Science Ventures focuses on creating and increasing early-stage Life Science firms with sturdy potential to realize world
success of their markets. Because the inception, Sunstone Life Science Ventures has invested in additional than 50 firms within the areas of prescription drugs, medical applied sciences and diagnostics, and has accomplished greater than 20 profitable IPOs and enormous M&A transactions. For extra data, please go to:

For additional data please contact:
Rewind Therapeutics
Anja Harmeier
Chief Govt Officer

Media Inquiries
Dr Ludger Wess / Ines-Regina Buth
Managing Companions
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68

Leave a Reply

Your email address will not be published. Required fields are marked *